Zoetis (ZTS) Other Non-Current Assets (2012 - 2026)
Zoetis (ZTS) reported Other Non-Current Assets of $351.0 million for Q1 2026, up 51.29% year-over-year from $232.0 million in Q1 2025, and up 7.34% quarter-over-quarter from $327.0 million in Q4 2025.
Zoetis (ZTS) Other Non-Current Assets (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Other Non-Current Assets data on file, last reported at $351.0 million in Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $351.0 million, up 51.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $351.0 million (up 51.29% YoY), and the FY2025 annual result was $327.0 million, up 30.8% from the prior year.
- Other Non-Current Assets climbed to $351.0 million in Q1 2026 per ZTS's latest filing, from $327.0 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $351.0 million in Q1 2026 and troughed at $129.0 million in Q1 2022.
- A 5-year average of $229.9 million and a median of $227.0 million in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets surged 88.44% in 2024, then slipped 18.1% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $147.0 million in 2022, then soared by 40.14% to $206.0 million in 2023, then advanced by 21.36% to $250.0 million in 2024, then surged by 30.8% to $327.0 million in 2025, then grew by 7.34% to $351.0 million in 2026.
- Business Quant data shows ZTS's Other Non-Current Assets at $351.0 million in Q1 2026, $327.0 million in Q4 2025, and $293.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 1.79 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 351.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 233.20 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 3.45 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 73.60 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 295.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 59.36 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 47.63 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Liquidia | 5.64 Bn | 5.42 Bn | 121.79 Mn | 3.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 351.00 Mn |
| Dec 31, 2025 | 327.00 Mn |
| Sep 30, 2025 | 293.00 Mn |
| Jun 30, 2025 | 267.00 Mn |
| Mar 31, 2025 | 232.00 Mn |
| Dec 31, 2024 | 250.00 Mn |
| Sep 30, 2024 | 314.00 Mn |
| Jun 30, 2024 | 326.00 Mn |
| Mar 31, 2024 | 227.00 Mn |
| Dec 31, 2023 | 206.00 Mn |
| Sep 30, 2023 | 216.00 Mn |
| Jun 30, 2023 | 173.00 Mn |
| Mar 31, 2023 | 143.00 Mn |
| Dec 31, 2022 | 147.00 Mn |
| Sep 30, 2022 | 161.00 Mn |
| Jun 30, 2022 | 147.00 Mn |
| Mar 31, 2022 | 129.00 Mn |
| Dec 31, 2021 | 111.00 Mn |
| Sep 30, 2021 | 112.00 Mn |
| Jun 30, 2021 | 97.00 Mn |